Hypofibrinolysis in type 2 diabetes: The role of the inflammatory pathway and complement C3

Diabetologia

Volumn 57, Issue 8, 2014, Pages 1737-1741

  Hess, Katharina ^a   Alzahrani, Saad H ^b,c   Price, Jackie F ^d   Strachan, Mark W ^e   Oxley, Natalie ^b   King, Rhodri ^b   Gamlen, Tobias ^b   Schroeder, Verena ^f   Baxter, Paul D ^g   Ajjan, Ramzi A ^b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c KING FAHAD MEDICAL CITY   (Saudi Arabia)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e WESTERN GENERAL HOSPITAL   (United Kingdom)

^f UNIVERSITY OF BERN   (Switzerland)

^g UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

C reactive protein; Complement C3; CRP; Diabetes; Fibrinolysis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; COMPLEMENT COMPONENT C3; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERGLYCEMIC AGENT; METFORMIN; NITRIC ACID DERIVATIVE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SULFONYLUREA;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASSOCIATION; BODY MASS; CHOLESTEROL BLOOD LEVEL; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EUGLOBULIN LYSIS TEST; FEMALE; FIBRINOLYSIS; HUMAN; HYPOFIBRINOLYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; TURBIDIMETRY; BLOOD; INFLAMMATION; MIDDLE AGED; PHYSIOLOGY;

AGED; C-REACTIVE PROTEIN; COMPLEMENT C3; DIABETES MELLITUS, TYPE 2; FEMALE; FIBRINOGEN; FIBRINOLYSIS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 84904732736     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3267-z     Document Type: Article

References (9)

1. Alzahrani SH, Ajjan RA (2010) Coagulation and fibrinolysis in diabetes. Diabetes Vasc Dis Res 7:260-273
2. Hess K, Alzahrani S, Mathai M et al (2012) A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3. Diabetologia 55:1103-1113
3. Alzahrani SH, Hess K, Price JF et al (2012) Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers. J Clin Endocrinol Metab 97: E2282-E2287
4. Schroeder V, Carter AM, Dunne J, Mansfield MW, Grant PJ (2010) Proinflammatory and hypofibrinolytic phenotype in healthy first-degree relatives of patients with type 2 diabetes. J Thromb Haemost 8:2080-2082
5. Price JF, Reynolds RM, Mitchell RJ et al (2008) The Edinburgh type 2 diabetes study: study protocol. BMC Endocr Disord 8:18
6. Yasojima K, Schwab C, McGeer EG, McGeer PL (2001) Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 21:1214-1219 (Pubitemid 34215153)
7. Széplaki G, Prohászka Z, Duba J et al (2004) Association of high serum concentration of the third component of complement (C3) with pre-existing severe coronary artery disease and new vascular events in women. Atherosclerosis 177:383-389 (Pubitemid 39505272)
8. Wei JN, Li HY, Sung FC et al (2012) Obesity and clustering of cardiovascular disease risk factors are associated with elevated plasma complement C3 in children and adolescents. Pediatr Diabetes 13:476-483
9. Amara U, Flierl MA, Rittirsch D et al (2010) Molecular intercommunication between the complement and coagulation systems. J Immunol 185:5628-5636